Kambhampati; Ramasastri

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kambhampati; Ramasastri.The latest application filed is for "combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist".

Company Profile

3.11.10

Kambhampati; Ramasastri - Telangana IN
KAMBHAMPATI; Ramasastri - Hyderabad Telangana
Kambhampati; Ramasastri - Andhra Pradesh IN

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Triple combination of pure 5-HT.sub.6 receptor antagonists, acetylcholinesterase inhibitors and NMDA receptor antagonist Grant 11,253,514 - Nirogi , et al. February 22, 2	2022-02-22
Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist Grant 11,116,764 - Nirogi , et al. September 14, 2	2021-09-14
Combination Of Pure 5-ht6 Receptor Antagonists With Nmda Receptor Antagonist App 20190175586 - NIROGI; Ramakrishna ; et al.	2019-06-13
Triple Combination Of Pure 5-ht6 Receptor Antagonists, Acetylcholinesterase Inhibitors And Nmda Receptor Antagonist App 20190160055 - NIROGI; Ramakrishna ; et al.	2019-05-30
Combination Of Pure 5-ht6 Receptor Antagonists With Acetylcholinesterase Inhibitors App 20190125743 - NIROGI; Ramakrishna ; et al.	2019-05-02
Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-- 1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite Grant 10,010,527 - Nirogi , et al. July 3, 2	2018-07-03
Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride Grant 9,802,896 - Nirogi , et al. October 31, 2	2017-10-31
Active Metabolite Of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-- 1h-indole Dimesylate Monohydrate And Dimesylate Dihydrate Salt Of Active Metabolite App 20170273944 - NIROGI; Ramakrishna ; et al.	2017-09-28
Process For Large Scale Production Of N-[4-(1-cyclobutyl Piperidin-4-yloxy) Phenyl]-2-(morpholin-4-yl) Acetamide Dihydrochloride App 20170260135 - NIROGI; Ramakrishna ; et al.	2017-09-14
Heteroaryl compounds as 5-HT.sub.4 receptor ligands Grant 9,636,335 - Nirogi , et al. May 2, 2	2017-05-02
Heteroaryl Compounds As 5-ht4 Receptor Ligands App 20150283125 - NIROGI; Ramakrishna ; et al.	2015-10-08
Heteroaryl compounds as 5-HT.sub.4 receptor ligands Grant 9,079,894 - Nirogi , et al. July 14, 2	2015-07-14
Compounds as histamine H3 receptor ligands Grant 9,079,888 - Nirogi , et al. July 14, 2	2015-07-14
Heterocyclyl compounds as histamine H.sub.3 receptor ligands Grant 8,912,179 - Nirogi , et al. December 16, 2	2014-12-16
Heterocyclyl Compounds As Histamine H3 Receptor Ligands App 20140148440 - Nirogi; Ramakrishna ; et al.	2014-05-29
Novel Compounds As Histamine H3 Receptor Ligands App 20140135304 - Nirogi; Ramakrishna ; et al.	2014-05-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.